2024-11-24 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products.

The cumulative return for LLY is 587.41%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 127.58%. The difference is 459.83%, placing it at the 68.58th percentile of its historical performance relative to the S&P 500 (based on the provided min/max range).  The provided alpha and beta values indicate consistent outperformance (positive alpha) relative to the market (beta consistently below 1, except for 2015-2017 and 2022-2024).  However, it's important to note that past performance does not guarantee future results.

**2. Recent Price Movement:**

* **Closing Price:** $747.79 (Last Market: $747.74)
* **5-Day Moving Average:** $741.61
* **20-Day Moving Average:** $799.84
* **60-Day Moving Average:** $873.92

The price is below all three moving averages, suggesting a downtrend in the short to medium term.

**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 37.12 - This indicates the stock is currently in oversold territory, suggesting potential for a price bounce.
* **PPO (Price Oscillator):** -0.56 - A negative value suggests bearish momentum.
* **Delta_Previous_Relative_Divergence:** -20.19 - Shows a recent relative weakening against the S&P 500.
* **Expected Return:** 169.79% - This is a significant potential long-term (2+ years) outperformance compared to the S&P 500 assuming consistent outperformance. However, this is merely a projection and not a guaranteed outcome.  The closing price of $747.74 is not significantly different from the last market price, not suggesting any recent rapid price movements (neither a sharp rebound nor a crash).


**4. Recent Financial Performance and Outlook:**

The provided earnings data shows some volatility.  While there were strong EPS figures in Q2 and Q3 2024, the Q1 2024 EPS was lower, and a loss was reported in Q4 2023.  A comprehensive analysis requires more data points and a detailed examination of the company's financial statements to understand the drivers behind these fluctuations. The provided revenue numbers show overall growth, despite some quarterly variations.  More context is needed to assess the most recent earnings relative to analyst expectations.

**6. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue has generally been increasing over the past year. Profit margins remain consistently high (around 80%), indicating strong profitability.
* **Capital and Profitability:** Equity has been growing. ROE (Return on Equity) has shown fluctuations, reflecting the volatility in earnings. The negative ROE in Q3 2023 needs further investigation.

**7. News and Recent Issues:**

* **(Requires further investigation):** This section needs to be populated with news from sources such as Shacknews and FINBOLD regarding recent earnings announcements, analyst opinions, market outlook, and performance highlights within the last 2 days.  This would provide crucial context for the analysis.

**8. Overall Summary:**

LLY has shown significant historical outperformance relative to the S&P 500, as evidenced by its high cumulative return.  However, the recent price action suggests a short-term downtrend, supported by the moving averages and negative PPO.  While the RSI indicates oversold conditions, potentially suggesting a bounce, the negative relative divergence and overall market sentiment (requiring further research from news sources) need to be considered. The company demonstrates generally strong profitability, though recent earnings reports show variability.  A long-term outlook is more positive, given the projected high expected return compared to the S&P 500, but this should be viewed cautiously.  A thorough investigation of recent news and analyst opinions is crucial to form a more complete and up-to-date assessment of the stock.  Finally, detailed analysis of Q4 2023 and Q1 2024 earnings and the reasons for negative ROE during a quarter would significantly enhance the understanding of the company's current financial position.

**9. Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.  Investing involves risk, including the potential loss of principal. Conduct thorough research and consult with a financial advisor before making any investment decisions.
